Even as Alnylam (ALNY)
works toward its second commercial drug filing, questions remain about
the safety and efficacy of givosiran, not to mention the platform as a
whole. But with good full Phase III data on givosiran and encouraging
open-label extension data on lumasiran over the last few days, the story
has gotten a little better in my view. These shares still remain
undervalued, but there remain numerous risks including FDA approval, the
efficacy and safety of the lead pipeline candidates, competition, and
challenges related to commercialization, including identifying patients
and securing reimbursement.
Read more here:
Data On Givosiran And Lumasiran Should Help The Alnylam Story
No comments:
Post a Comment